Microspheres as a drug delivery system in cancer therapy

Bibliography

• CUMMINGS J, SMYTH JF: In: Pharmaceutical Aspects of Cancer Chemotherapy. Florence AT, Sable EG (Eds.), Butterworth-Heineman, Oxford (1993) 27–53.
   Google Scholar
• •Comprehensive review of anticancer drug delivery systems including a large section of microspheres.
   Google Scholar
• UNGER C: Current concepts of treatment in medicaloncology: new anticancer drugs. J. Cancer Res. Clin. On-col. (1996) 122:189–198.
   PubMed Web of Science ®Google Scholar
• ROTH JA, CRISTIANO RJ: Gene therapy for cancer: whathave we done and where are we going? J. Nati Cancer Inst. (1997) 89:21–39.
   PubMed Web of Science ®Google Scholar
• CHO MJ, JULIANO R: Macromolecular versus small-molecule therapeutics: drug discovery, developments and clinical considerations. Trends Biotech. (1996) 14:153–158.
   PubMed Web of Science ®Google Scholar
• •Thought provoking commentary on the merits and demerits of developing macromolecular drugs such polymeric deliv-ery systems over conventional small molecules.
   Google Scholar
• WIDDER KJ, SENYEI AE, RANNEY DR: Magnetically guided microspheres for the biophysical targeting of antitumour agents. Adv. Pharmacol. Chemother. (1979) 16:213–271.
   PubMedGoogle Scholar
• RAVIKUMAR HR, DHANARAJ SA, RAJENDRAN D, DUBE R, SURESH B: Distribution of etoposide-loaded hydro-philic albumin microspheres in mice. Drug Dev. Ind. Pharm. (1996) 22:1005–1008.
   Web of Science ®Google Scholar
• WILLMOTT N: Chemoembolisation in regional cancer chemotherapy: a rationale. Cancer Treat. Rev. (1987) 14:143–156.
   PubMedGoogle Scholar
• WILLMOTT N, CUMMINGS J, STUART JFB, FLORENCE AT: Adriamycin loaded albumin microspheres: prepara-tion, in vivo distribution and release in the rat. Bio-pharm. Drug. Dispos. (1985) 6:91–104.
   PubMed Web of Science ®Google Scholar
• JEYANTHI R, PANDURANGA RAO K: Preparation of gela-tin microspheres of bleomycin. Intern. J. Pharm. (1987) 35:177–179.
   Web of Science ®Google Scholar
• TSAI DC, HOWARD SA, HOGAN TF, MALANGA CJ, KANDZARI SJ, MA JKH: Preparation and in vitro evalua-tion of polylactic acid-mitomycin C microcapsules. J. Microencap. (1986) 3:181–193.
   PubMedGoogle Scholar
• JALIL R: Biodegradable poly (lactic) and poly (lactide-co-glycolide) polymers in sustained drug delivery. Drug Dev. Ind. Pharm. (1990) 16:2353–2367.
   Web of Science ®Google Scholar
• ONISIHI H, SHIMODA J, MACHIDA Y: Chitosan-drug con-jugate microspheres: preparation and drug release properties of microspheres composed of the conju-gate of 2' or 3'(4-caboxy-butury1)-5-fluorouridine with chitosan. Drug Dev. Ind. Pharm. (1996) 22:457–463.
   Web of Science ®Google Scholar
• POPA M-I, AELENI N, IONESCU G: Preparation of 2,3 di-carboxycellulose microspheres containing antitu-mour agent as a drug carrier. Cellulose Chem. Tech. (1996) 30:33–38.
   Google Scholar
• LIU L-S, LIU S-Q, NG SY, FROIX M, OHNO T, HELLER J: Controlled release of interleukin-2 for tumour immu-notherapy using alginate/chitosan porous micro-spheres. J. Contrl. Rel. (1997) 43:65–74.
   Google Scholar
• ••Alginate/chitosan microspheres are demonstrated to be a vi-able alternative to PLGA microspheres normally used for controlled release of cytokines. The alginate/chitosan parti-cles were able to sustain the release of IL-2 for 5 days with-out affecting biological potency of the cytokine.
   Google Scholar
• JONES C, BURTON MA, GRAY BN: In vitro release of cy-totoxic agents from ion exchange resins. J. Contrl. Rel. (1989) 8:251–257.
   Google Scholar
• TAKENAGA M: Application of lipid microspheres for the treatment of cancer. Adv. Drug Deliv. Rev. (1996) 20:209–219.
   Web of Science ®Google Scholar
• FUJIMOTO S, ENDOH F, KITSUKAWA Y et al: Continued in vitro and in vivo release of an antitumour drug from albumin microspheres. Experientia (1983) 39:913–916.
   PubMedGoogle Scholar
• OKADA H, YAMAMOTO M, HEYA T et al.: Drug delivery using biodegradable microspheres. J. Contrl. Rel. (1994) 28:121–129.
   Web of Science ®Google Scholar
• ••The mechanism through which PLGA microspheres encap-sulate a water soluble anticancer peptide is elucidated. The microspheres were formed by solvent evaporation of a w/o/w emulsion and a number of physical techniques were employed to visualise the incorporated peptide.
   Google Scholar
• CHEN L, APTE RN, COHEN S: Characterisation of PLGA microspheres for the controlled delivery of IL-la for tumour immunotherapy. J. Contrl Rel. (1997) 43:261–272.
   Web of Science ®Google Scholar
• •A variety of different polymer chain lengths and co-polymer ratios were investigated to study systematically how differ-ent pharmaceutical properties of PLGA systems affect thera-peutic efficacy of IL-la microspheres used in tumour immunotherapy. Significant degradation of the cytokine oc-curred with all formulations.
   Google Scholar
• GOLUMBEK PT, AZHARI R, JAFFEE EM et al: Controlled release, biodegradable cytokine depots: a new ap-proach in cancer vaccine design. Cancer Res. (1993) 53:5841–5844.
   PubMed Web of Science ®Google Scholar
• •Protein microspheres manufactured from a mixture of gela-tin and chondroitin sulfate containing the cytokine CM-CSF are shown to be effective in boosting immunity in mice against a challenge from tumour cells.
   Google Scholar
• MATHIOWITZ E, JACOB JS, JONG YS et al.: Biologically erodable microspheres as potential oral drug delivery systems. Nature (1997) 386:410–414.
   PubMed Web of Science ®Google Scholar
• ••First report of successful oral administration of gene therapyutilising bioadhesive microspheres. A new method, referred to as phase inversion nanoencapsulation, is described for preparation of particles.
   Google Scholar
• TSUNG M, BURGESS DJ: Preparation and stabilization of heparin/gelatin complex coacervate microcapsules. J. Pharm. Sci. (1997) 86:603–607.
   PubMed Web of Science ®Google Scholar
• POSTE G, KIRSH R: Site-specific (targeted) drug delivery in cancer chemotherapy. Biotechnology (1983) 1:869–873.
   Google Scholar
• TOMLINSON E: Microsphere delivery systems for drugtargeting and controlled release. Intern. J. Pharm. Tech. Prod. Man. (1983) 4:49–57.
   Google Scholar
• MAHATO RI, TAKAKURA Y, HASHIDA M: Nonviral vec-tors for the in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit. Rev. Ther. Drug Carrier Sys. (1997) 14:133–172.
   PubMed Web of Science ®Google Scholar
• TOMLINSON E, ROLLAND AP: Controllable gene ther-apy; pharmaceutics of non-viral gene delivery sys-tems. J. Contrl. Rel. (1996) 39:357–373.
   Web of Science ®Google Scholar
• WEINSTEIN JN, LESERMAN LD: Liposomes as drug carri-ers in cancer chemotherapy. Pharmacol. Ther. (1984) 24:207–233.
   PubMed Web of Science ®Google Scholar
• WIDDER KJ, SENYEI AE, SCARPELLI DG: Magnetic micro-spheres: a model system for site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. (1978) 158:141–151.
   PubMed Web of Science ®Google Scholar
• GUPTA PK, HUNG CT: Effect of carrier dose on the mul-tiple tissue disposition of doxorubicin hydrochloride administered via magnetic albumin microspheres in rats. J. Pharm. Sci. (1989) 78:745–748.
   PubMed Web of Science ®Google Scholar
• WIDDER KJ, MORRIS RM, POORE GA, HOWARD DP, Jr., SENYEI AE Tumour remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres. Proc. Natl. Acad. Sci. USA (1981) 78:579–583.
   Google Scholar
• GOLDBERG JA, BRADMAN MS, KERR DJ et al.: Single pho- ton emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tu-mour targeting by microspheres with angiotensin II. Nucl. Med. Commun. (1987) 8:1025–1032.
   PubMedGoogle Scholar
• •Clinical studies demonstrating convincingly that albumin microspheres can achieve a high degree of second order tar-geting to colorectal liver metastases after hepatic artery in-jection in conjunction with the vasoconstrictor angiotensin
   Google Scholar
• WANG YM, SATO H, ADACHI I, HORIKOSHI I: Prepara- tion and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem. Pharm. Bull. (1996) 44:1935–1940.
   PubMed Web of Science ®Google Scholar
• CLELAND JL, JONES AJS: Stable formulations of recom- binant human growth hormone and interferon-gamma for microencapsulation in biodegradable mi-crospheres. Pharm. Res. (1996) 13:1464–1475.
   PubMed Web of Science ®Google Scholar
• •A number of excipients were added to PLGA during forma-tion of microspheres in order to stabilise encapsulated polypeptides. Trehalose was found to be completely effec-tive in preserving stability.
   Google Scholar
• JAMEELA SR, SUMA N, MISRA A et al.: Poly(e-capro- lac- tone) microspheres as a vaccine carrier. Curr. Sci. (1996) 70:699–671.
   Google Scholar
• •Poly(e-caprolactone) is shown to be a viable alternative to PLGA as a slow release preparation of antigens for immuni-sation. Acidification of the particles was avoided due to ultra-slow biodegradation of particles.
   Google Scholar
• CUMMINGS J, WILLMOTT N, MARLEY E, SMYTH JF: Cova- lent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition. Biochem. Pharmacol. (1991) 41:1849–1854.
   PubMed Web of Science ®Google Scholar
• WILLMOTT N, MCGEE GA, CUMMINGS J, HALBERT GW, SMYTH JF: Doxorubicin-loaded casein microspheres: protean nature of drug incorporation. J. Pharm. Phar-macol. (1992) 44:472–475.
   PubMed Web of Science ®Google Scholar
• MINOW RA, BENJAMIN RS, LEE ET: Adriamycin cardio-myopathy: risk factors. Cancer (1977) 39:1397–1402.
   PubMed Web of Science ®Google Scholar
• ENDICOTT JA, LING V: The biochemistry of p-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem. (1989) 58:137–156.
   PubMed Web of Science ®Google Scholar
• CASSIDY J, NEWELL D, CUMMINGS J: In: Cancer Surveys: The Pharmacokinetics of Chemotherapy. Workman P, Gra-ham MA (Eds.), Cold Spring Harbour Laboratory Press, Plainview (1993) Chapter 13, 315–341.
   Google Scholar
• KERR DJ, WILLMOTT N, MCKILLOP JH, CUMMINGS J, LEWI HJ, MCARDLE CS: Target organ disposition and plasma pharmacokinetics of doxorubicin incorporated into albumin microspheres after intrarenal arterial ad-ministration. Cancer (1988) 62:878–883.
   PubMed Web of Science ®Google Scholar
• •Doxorubicin albumin microspheres for chemoembolisation are shown in rabbits to offer a pharmacokinetic advantage of a 106-fold improvement over systemic administration of free drug.
   Google Scholar
• MCARDLE CS, LEWI H, HANSELL D, MCKILLOP J, WILL-MOTT N: Cytotoxic-loaded albumin microspheres: a novel approach to regional chemotherapy. Br. J. Surg. (1988) 75:132–134.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, WATSON DS, SMYTH JF: Drug analysis of protein microspheres: from pharmaceutical prepara-tion to in vivo fate. In: Microspheres and Regional Cancer Therapy. Willmott N, Daly J (Eds.), CRC Press, Boca Raton (1993) 141–166.
   Google Scholar
• CUMMINGS J, MCARDLE CS: Studies on the in vivo dispo-sition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer (1986) 53:835–838.
   PubMed Web of Science ®Google Scholar
• WILLMOTT N, CUMMINGS J: Increased antitumour ef- fect of adriamycin-loaded albumin microspheres is as-sociated with anaerobic bioreduction of drug in tumour tissue. Biochem. Pharmacol. (1987) 36:521–526.
   PubMed Web of Science ®Google Scholar
• •First report of protein microspheres actively altering biore-ductive metabolism of an anticancer drug (doxorubicin).
   Google Scholar
• CHEN Y, WILLMOTT N, ANDERSON J, FLORENCE AT: Hae-moglobin, transferrin and albumin/polyaspartic acid microspheres as carriers for the cytotoxic drug adria-mycin. 1. Ultrastructural appearance and drug con-tent. J. Contd. Rel. (1988) 8:93–101.
   Google Scholar
• CUMMINGS J WILLMOTT N, MARLEY EC, SMYTH JF: Cor-relation between tumour drug disposition and the an-titumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of action. Biochem. Pharmacol (1993) 45:2550–2553.
   PubMedGoogle Scholar
• ••By employing a series of protein microspheres composedfrom a variety of materials and exhibiting different pharma-ceutical properties, the optimal form of drug delivery of doxorubicin to solid tumours was established.
   Google Scholar
• CUMMINGS J, ANDERSON L, WILLMOTT N, SMYTH JF: Themolecular pharmacology of doxorubicin in vivo. Eur. J. Cancer (1991) 27:532–535.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, ALLAN LJ, WILLMOTT N, RILEY R, WORK-MAN P, SMYTH JF: The enzymology of doxorubicin qui-none reduction in tumour tissue. Biochem. Pharmacol. (1992) 44:2175–2183.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, WILLMOTT N, HOEY BM, MARLEY ES, SMYTH JF: The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Biochem. Pharmacol. (1992) 44:2165–2174.
   PubMed Web of Science ®Google Scholar
• IKE 0, SHIMIZU Y, IKADA Y et al.: Biodegradation andantitumour effect of adriamycin-containing poly(1,-lactic acid) microspheres. Biomaterials (1991) 12:757–762.
   Google Scholar
• IKE 0, SHIMIZU Y, HITOMI, S: Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly (L-lactic acid) microspheres. Chest (1991) 99:911–915.
   PubMed Web of Science ®Google Scholar
• TOKES ZA, ROGERS KE, REMBAUM A: Synthesis of adriamycin-coupledpolyglutaraldehyde microspheres and evaluation of their cytostatic activ- ity. Proc. Natl. Acad. ScL USA (1982) 79:2026–2030.
   PubMed Web of Science ®Google Scholar
• •Covalent coupling of doxorubicin to polyglutaraldehyde mi-crospheres overcomes drug-resistance possibly via activa-tion of novel mechanisms of drug action.
   Google Scholar
• TRITTON T, YEE G: The anticancer agent adriamycincan be actively cytotoxic without entering cells. Sci-ence (1982) 217:248–250
   PubMed Web of Science ®Google Scholar
• CHEN Y, BURTON MA, CODDE JP, NAPOLI S, MARTINS IJ,GRAY BN: Evaluation of ion-exchange microspheres as carriers for the anticancer drug doxorubicin: in vitro studies. J. Pharm. Pharmacol. (1992) 44:211–215.
   PubMed Web of Science ®Google Scholar
• CARTER SK, CROOKE ST: Mitomycin C: current status andnew developments. Academic Press, New York (1979).
   Google Scholar
• ENSMINGER WD, GYVES JW, STETSON P, WALKER-ANDREWS S: Phase I study of hepatic arterial degrad-able starch microspheres and mitomycin. Cancer Res. (1985) 45:4464–4467.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO S, MIYAZAKI M, ENDOH F et al. Mitomycin Ccarrying microspheres as a novel method of drug de-livery. Cancer Drug Del. (1985) 2:173–181.
   PubMedGoogle Scholar
• FUJIMOTO S, MIYAZAKI M, ENDOH F et al: Effects ofintra-arterially infused biodegradable microspheres containing mitomycin C. Cancer (1985) 55:522–532.
   PubMedGoogle Scholar
• FUJIMOTO S, SHRESTHA RD, OHTA M, OKUI K, MORI-MOTO Y: Mitomycin C microspheres and intra-arterial cancer chemotherapy. (Unpublished).
   Google Scholar
• BEIJNEN JH, LINGEMAN H, VAN MUNSTER HA, UNDER-BERG WJM: Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability. J. Pharm. Biomed. Ann. (1986) 4:275–295.
   PubMed Web of Science ®Google Scholar
• MEHTA RC, HOGAN TF, MARDMOMEN S, MA JHK: Chro-matographic studies of mitomycin C degradation in al-bumin microspheres. J. Chromatogr. (1988) 430:341–349.
   PubMed Web of Science ®Google Scholar
• •Methods extensively used to form albumin microspheres containing mitomycin C are shown to significantly degrade the drug.
   Google Scholar
• NATSUME H, SUGIBAYASHI K, JUNI K, MORIMOTO Y, SHIBATA T, FUJIMOTO S: Preparation and evaluation of biodegradable albumin microspheres containing mi-tomycin C. Intern. J. Pharm. (1990) 58:79–87.
   Google Scholar
• WHATELEY TL, ELEY JG, KERR DJ eta].: Incorporation ofmitomycin C into microspheres of biodegradable poly(lactide-glycolide) co-polymers. Abstracts Papers Am. Chem. Soc. (1992) 203:59.
   Google Scholar
• ALLAN L, CUMMINGS J, WILLMOTT N, WHATELEY TL, SMYTH JF: Incorporation and release of chemically in-tact mitomycin C from albumin microspheres: a high performance liquid chromatography evaluation. J. Drug Target. (1993) 1:317–323.
   PubMed Web of Science ®Google Scholar
• •A novel method is developed to encapsulate mitomycin C chemically intact in albumin microspheres and to ensure the release of chemically intact drug.
   Google Scholar
• CUMMINGS J, ALLAN L, SMYTH JF: Encapsulation of mi- tomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action. Biochem. Pharma-col. (1994) 47:1345–1356.
   PubMedGoogle Scholar
• •The optimal form of drug delivery of mitomycin C to solid tumours is established.
   Google Scholar
• GARDINER J, RITHCIE AA, CUMMINGS J, JODRELL DI, SMYTH JF: Encapsulation of the indoloquinone E09 as potential therapy for the treatment of colorectal liver metastases. Br. J. Cancer (1996) 73 (Suppl. XXVI):28.
   Google Scholar
• ABE R, AKIYOSHI T, TSUJI H, BABA T: Two-route chemo-therapy using intra-arterial ciplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. Eur. J. Cancer Clin. Oncol. (1988) 24:1671–1685.
   PubMedGoogle Scholar
• NOTEBORN HPJM, VAROSSIEAU F, BLANKEN G, BURGER JJ, MCVIE JG: Clinical pharmacokinetics of cisplatin in intra-arterial carrier-mediated delivery in treatment of metastatic liver cancer. Proc. Intern. Symp. Contrl Rel. Bioact. Mater. (1988) 15:127.
   Google Scholar
• VERRIJK R, SMOLDERS IJH, MCVIE JG, BEGG AC: Polymer-coated albumin microspheres as carriers for intravascular tumour targeting of cisplatin. Cancer Chemother. Pharamcol (1991) 29:117–121.
   PubMedGoogle Scholar
• •A novel approach is adopted to prevent the burst effect and rapid release of cisplatin from albumin microspheres by coating particles in PLGA.
   Google Scholar
• ITO K, TABATA C-Y, IKE 0 eta].: In vivo suppressive ef-fects of co-poly(glycolich-lactic acid) microspheres containing CDDP on murine tumor cells. J. Contrl Rel. (1996) 42:175–184.
   Google Scholar
• HAGIWARA A, TAKAHASHI T, KOJIMA 0 et al: Pharma-cologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents. Cancer (1993) 71:844–850.
   PubMed Web of Science ®Google Scholar
• KUMAGAI S, SUGIYAMA T, NISHIDA T, USHIJIMA K, YA-KUSHIJI M: Improvement of intraperitoneal chemo-therapy for rat ovarian cancer using cisplatin-containing microspheres. Jpn. J. Cancer Res. (1996) 87:412–417.
   PubMedGoogle Scholar
• WANG YM, SATO H, ADACHI S, HORIKOSHI I: Optimiza-tion of the formulation design of chitosan micro-spheres containing ciplatin. J. Pharm. Sci. (1996) 85:1204–1210.
   PubMed Web of Science ®Google Scholar
• GUPTA PK: Drug targeting in cancer chemotherapy: a clinical perspective. J. Pharm. Sci. (1990) 79:949–962.
   PubMedGoogle Scholar
• CIFTCI K, KAS HS, HINCAL AA, ERCAN TM, GUVEN 0, RUACAN S: In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil pre-pared by a solvent evaporation method. Intern. J. Pharm. (1996) 131:73–82.
   Web of Science ®Google Scholar
• HAGIWARA A, TAKAHASHI T, SAWAI K et al.: Pharma-cological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. Br. J. Cancer (1996) 74:1392–1396.
   PubMedGoogle Scholar
• HAGIWARA A, SAKAKURA C, TSUJIMOTO H et al: Selec-tive delivery of 5-fluorouracil (5-FU) to tissues using 5-FU microspheres in rats. Anti-Cancer Drugs (1997) 8:182–188.
   PubMed Web of Science ®Google Scholar
• NARAYANI R, PANDURANGA RAO K: Gelatin micro-spheres cocktails of different sizes for the controlled release of anticancer drugs. Intern. J. Pharm. (1996) 143:255–258.
   Google Scholar
• JAMEELA SR, LATHA PG, SUBRAMONIAN A, JAY-AKRISHNAN A: Antitumour activity of mitoxantrone-loaded chitosan microspheres against Ehrlich ascites carcinoma. J. Pharm. Pharmacol. (1996) 48:685–688.
   PubMed Web of Science ®Google Scholar
• MI F-L, CHEN C-T, TSENG Y-C, KUAN C-Y, SHYU S-S:Iron(HO-carboxymethylchitin microsphere for the pH-sensitive release of 6-mercaptopurine. J. Contrl. Rel. (1997) 44:19–32.
   Google Scholar
• NARAYANI R, PANDURANGA RAO K: Solid tumor che-motherapy using injectable gelatin microspheres con-taining free methotrexate and conjugated methotrexate. Intern. J. Pharm. (1996) 142:25–32.
   Web of Science ®Google Scholar
• FUJIN° M, FUKUDA T, SHINAGAWA S et al.: Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem. Bio-phys. Res. Commun. (1974) 60:406–413.
   Google Scholar
• ANDERSON PM: Delivery systems for immunomodula-tory proteins and peptides. BioDrugs (1997) 7:51–65.
   PubMedGoogle Scholar
• •A comprehensive review of delivery systems for immuno-modulatory proteins and peptides.
   Google Scholar
• HORA MS, RANA RK, NUNBERG JH et al.: Controlled re-lease of interleukin-2 from biodegradable micro-spheres. Biotechnology (1990) 8:755–758.
   PubMed Web of Science ®Google Scholar
• DONOHUE JH, ROSENBERG SA: The fate of interleukin-2 after in vivo administration. J. Immunol (1983) 130:2203–2208.
   PubMed Web of Science ®Google Scholar
• STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• AKHTAR S, IVINSON AJ: Therapies that make sense. Na-ture Genet. (1993) 4:215–217.
   PubMedGoogle Scholar
• LEWIS KJ, IRWIN WJ, AKHTAR S: Biodegradable poly(t-lactic acid) matrices for the sustained delivery of antisense oligonucleotides. j Contrl. Rel. (1995) 37:173–183.
   Web of Science ®Google Scholar